Results 151 to 160 of about 26,368 (251)
Opioids in breast cancer: Between analgesia and modulation of tumour progression
British Journal of Pharmacology, Volume 183, Issue 9, Page 1727-1746, May 2026.Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun +2 more
wiley +1 more source
Drug Design, Development and Therapy, 2018 Cesare Gridelli,1 Tianlei Chen,2 Amy Ko,2 Mary E O’Brien,3 Teng Jin Ong,4 Mark A Socinski,5 Pieter E Postmus6 1Division of Medical Oncology, S. G.
Gridelli C +6 more
doaj
Cancer Science, Volume 117, Issue 5, Page 1422-1433, May 2026.In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno +6 more
wiley +1 more source
Aggressive squamous cell carcinomas arising from mucosal lichen planus: A report of three cases
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Neda Cramer +5 more
wiley +1 more source
Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study. [PDF]
Ther Adv Med OncolTseng KY +4 more
europepmc +1 more source
Correction: Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer. [PDF]
Sci RepSezgin Y +41 more
europepmc +1 more source